AI
AZN icon

Axiom Investors’s AstraZeneca AZN Stock Holding History

Axiom Investors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.59M Sell
34,746
-27,982
-45% -$5.26M 0.06% 103
2026
Q1 		$12.4M Buy
+62,728
New +$12.1M 0.14% 65
2024
Q4 		– Sell
-222,254
Closed -$34.6M – 137
2024
Q3 		$34.6M Buy
+222,254
New +$35.9M 0.3% 43
2023
Q4 		– Sell
-5,300
Closed -$718K – 137
2023
Q3 		$718K Sell
5,300
-460,995
-99% -$63M 0.01% 121
2023
Q2 		$66.7M Buy
466,295
+22,659
+5% +$3.33M 0.99% 30
2023
Q1 		$61.6M Sell
443,636
-910,569
-67% -$123M 1.01% 31
2022
Q4 		$184M Buy
1,354,205
+182,775
+16% +$22.9M 3.61% 6
2022
Q3 		$128M Buy
1,171,430
+410,177
+54% +$52M 2.7% 11
2022
Q2 		$101M Buy
+761,253
New +$99.9M 3.02% 10
2020
Q4 		– Sell
-666,035
Closed -$73M – 128
2020
Q3 		$73M Buy
666,035
+28,075
+4% +$3.12M 1.18% 22
2020
Q2 		$67.5M Buy
637,960
+78,725
+14% +$8.13M 1.33% 22
2020
Q1 		$50M Buy
559,235
+15,945
+3% +$1.5M 1.27% 20
2019
Q4 		$54.2M Sell
543,290
-64,895
-11% -$6.11M 1.26% 22
2019
Q3 		$54.2M Buy
608,185
+104,305
+21% +$9.04M 1.46% 23
2019
Q2 		$41.6M Buy
503,880
+119,072
+31% +$9.34M 1.14% 29
2019
Q1 		$31.1M Sell
384,808
-225
-0.1% -$17.7K 0.96% 29
2018
Q4 		$29.2M Buy
+385,033
New +$30.1M 1.02% 29

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Axiom Investors's AZN Position: Q2 2026 in Review

Axiom Investors reduced its AstraZeneca (AZN) stake by 45% in Q2 2026, selling an estimated $5.26M and leaving 34,746 shares worth $6.59M. The position accounts for 0.06% of the portfolio, ranked #103.

Axiom Investors first reported a position in AZN in Q4 2018 and has held it in 17 quarters since. The position peaked at $184M in Q4 2022. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Axiom Investors held 34,746 shares of AstraZeneca worth $6.59M as of Q2 2026.
  • Axiom Investors sold 27,982 AstraZeneca shares in Q2 2026, an estimated $5.26M.
  • AstraZeneca made up 0.06% of Axiom Investors's portfolio in Q2 2026, its #103 holding.
  • Axiom Investors first reported a position in AstraZeneca in Q4 2018 and has held it in 17 quarters since.
  • Axiom Investors's AstraZeneca position peaked at $184M in Q4 2022.
  • 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Axiom Investors's 13F filing for Q2 2026, filed 12 Aug 2026.